文献速递临床试验与 GCP流行病学与生物统计

危重症COVID-19患者皮质类固醇治疗:随机试验前瞻性荟萃分析方案的结构化摘要

Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials.
PubMed 文献 · Trials · 2020-08-24

本方案计划开展前瞻性荟萃分析,纳入住院危重症疑似或确诊COVID-19患者的随机对照试验,评估皮质类固醇对比常规治疗或安慰剂对随机化后28天内全因死亡率的影响,并分析亚组效应及严重不良事件。

要点

  • 主要结局为随机化后28天内全因死亡率。
  • 纳入安慰剂对照及开放标签随机试验。
  • 将按剂量(以氢化可的松400 mg/天或等效剂量为界)分类并行网络荟萃分析。

核心结论

  • 方案旨在评估皮质类固醇对危重症COVID-19患者28天死亡率的效果及亚组差异。

研究设计与样本

  • 前瞻性随机对照试验的荟萃分析,纳入住院危重症疑似或确诊COVID-19患者。
  • 干预为治疗剂量的地塞米松、氢化可的松或甲泼尼龙,静脉或口服,随机化后立即给药。
  • 对照为常规治疗、标准治疗或安慰剂。

关键数值与推荐

  • 主要结局:随机化后28天内全因死亡率。
  • 类固醇剂量以氢化可的松400 mg/天或等效剂量为界分类为高剂量或低剂量。
  • 主要分析采用固定效应模型,并采用随机效应模型(Paule-Mandel异质性估计和Hartung-Knapp调整)。
  • 使用I2统计量量化试验间效应不一致性。
  • 使用GRADE评估证据确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Primary objective: To estimate the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization. Secondary objectives: To examine whether the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization varies between subgroups related to treatment characteristics, disease severity at the time of randomization, patient characteristics, or risk of bias. To examine the effect of corticosteroids compared with usual care or placebo on serious adverse events. STUDY DESIGN: Prospective meta-analysis of randomized controlled trials. Both placebo-controlled and open-label trials are eligible. PARTICIPANTS: Hospitalised, critically ill patients with suspected or confirmed COVID-19. INTERVENTION AND COMPARATOR: Intervention groups will have received therapeutic doses of a steroid (dexamethasone, hydrocortisone or methylprednisolone) with IV or oral administration immediately after randomization. The comparator groups will have received standard of care or usual care or placebo. MAIN OUTCOME: All-cause mortality up to 28 days after randomization. SEARCH METHODS: Systematic searching of clinicaltrials.gov , EudraCT, the WHO ISRCTN registry, and the Chinese clinical trials registry. Additionally, research and WHO networks will be asked for relevant trials. RISK OF BIAS ASSESSMENTS: These will be based on the Cochrane RoB 2 tool, and will use structured information provided by the trial investigators on a form designed for this prospective meta-analysis. We will use GRADE to assess the certainty of the evidence. STATISTICAL ANALYSES: Trial investigators will provide data on the numbers of participants who did and did not experience each outcome according to intervention group, overall and in specified subgroups. We will conduct fixed-effect (primary analysis) and random-effects (Paule-Mandel estimate of heterogeneity and Hartung-Knapp adjustment) meta-analyses. We will quantify inconsistency in effects between trials using I2 statistics. Evidence for subgroup effects will be quantified by ratios of odds ratios comparing effects in the subgroups, and corresponding interaction p-values. Comparisons between subgroups defined by trial characteristics will be made using random-effects meta-regression. Comparisons between subgroups defined by patient characteristics will be made by estimating trial-specific ratios of odds ratios comparing intervention effects between subgroups then combining these using random-effects meta-analysis. Steroid interventions will be classified as high or low dose according to whether the dose is greater or less than or equal to 400 mg hydrocortisone per day or equivalent. We will use network meta-analysis methods to make comparisons between the effects of high and low dose steroid interventions (because one trial randomized participants to both low and high dose steroid arms). PROSPERO REGISTRATION NUMBER: CRD42020197242 FULL PROTOCOL: The full protocol for this prospective meta-analysis is attached as an additional file, accessible from the Trials website (Additional file 1). To expedite dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol for the systematic review.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sterne JAC, Diaz J, Villar J, et al. Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. Trials. 2020. PMID: 32831155. doi:10.1186/s13063-020-04641-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。